CN112040976A - 奈莫利珠单抗对具有中至重度表皮脱落的异位性皮炎的治疗 - Google Patents

奈莫利珠单抗对具有中至重度表皮脱落的异位性皮炎的治疗 Download PDF

Info

Publication number
CN112040976A
CN112040976A CN201980024489.7A CN201980024489A CN112040976A CN 112040976 A CN112040976 A CN 112040976A CN 201980024489 A CN201980024489 A CN 201980024489A CN 112040976 A CN112040976 A CN 112040976A
Authority
CN
China
Prior art keywords
weeks
exfoliation
equivalent
subject
nemolizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980024489.7A
Other languages
English (en)
Chinese (zh)
Inventor
纳比尔·克鲁什
广川惠子
三原良介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Original Assignee
Nestle Skin Health SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Skin Health SA, Chugai Pharmaceutical Co Ltd filed Critical Nestle Skin Health SA
Publication of CN112040976A publication Critical patent/CN112040976A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980024489.7A 2018-02-09 2019-02-08 奈莫利珠单抗对具有中至重度表皮脱落的异位性皮炎的治疗 Pending CN112040976A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
US62/628,714 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
CN112040976A true CN112040976A (zh) 2020-12-04

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024489.7A Pending CN112040976A (zh) 2018-02-09 2019-02-08 奈莫利珠单抗对具有中至重度表皮脱落的异位性皮炎的治疗

Country Status (23)

Country Link
US (2) US12435147B2 (https=)
EP (2) EP4644424A3 (https=)
JP (3) JP7777921B2 (https=)
CN (1) CN112040976A (https=)
AU (2) AU2019219608B2 (https=)
BR (1) BR112020016144A2 (https=)
CA (1) CA3090062A1 (https=)
CL (1) CL2020002050A1 (https=)
DK (1) DK3749353T3 (https=)
ES (1) ES3049513T3 (https=)
FI (1) FI3749353T3 (https=)
HR (1) HRP20251101T1 (https=)
IL (1) IL276524A (https=)
LT (1) LT3749353T (https=)
MX (1) MX2020008193A (https=)
PH (1) PH12020551185A1 (https=)
PL (1) PL3749353T3 (https=)
PT (1) PT3749353T (https=)
RU (1) RU2758378C1 (https=)
SG (1) SG11202007558YA (https=)
SI (1) SI3749353T1 (https=)
TW (1) TWI856006B (https=)
WO (1) WO2019155427A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614016A (zh) * 2015-04-14 2018-01-19 中外制药株式会社 包含il‑31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614016A (zh) * 2015-04-14 2018-01-19 中外制药株式会社 包含il‑31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O. NEMOTO等: "The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study", BRITISH JOURNAL OF DERMATOLOGY, vol. 174 *
THOMAS RUZICKA等: "Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 376, no. 9, pages 5 *

Also Published As

Publication number Publication date
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
CL2020002050A1 (es) 2020-12-11
IL276524A (en) 2020-09-30
HRP20251101T1 (hr) 2025-11-21
JP2021512917A (ja) 2021-05-20
TW201941800A (zh) 2019-11-01
BR112020016144A2 (pt) 2020-12-15
WO2019155427A1 (en) 2019-08-15
PH12020551185A1 (en) 2021-05-17
SG11202007558YA (en) 2020-09-29
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
EP4644424A2 (en) 2025-11-05
TW202448919A (zh) 2024-12-16
RU2758378C1 (ru) 2021-10-28
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
US20200385476A1 (en) 2020-12-10
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
JP2023182632A (ja) 2023-12-26
AU2019219608B2 (en) 2025-10-16
DK3749353T3 (da) 2025-09-01
CA3090062A1 (en) 2019-08-15
SI3749353T1 (sl) 2025-10-30
JP7777921B2 (ja) 2025-12-01
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
EP3749353B1 (en) 2025-07-30
US20260008859A1 (en) 2026-01-08
PT3749353T (pt) 2025-10-14
EP4644424A3 (en) 2026-01-14
FI3749353T3 (fi) 2025-09-10

Similar Documents

Publication Publication Date Title
TWI738648B (zh) 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
CA3228708A1 (en) Treatment of atopic dermatitis
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: La tourdepe, Switzerland

Applicant after: Gaodemei Holding Co.,Ltd.

Applicant after: Chugai Pharmaceutical Co.,Ltd.

Address before: Lausanne

Applicant before: NESTLe SKIN HEALTH S.A.

Applicant before: Chugai Pharmaceutical Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Swiss Express

Applicant after: Gaodemei Holding Co.,Ltd.

Applicant after: Chugai Pharmaceutical Co.,Ltd.

Address before: Swiss Latour Depe

Applicant before: Gaodemei Holding Co.,Ltd.

Applicant before: Chugai Pharmaceutical Co.,Ltd.

CB02 Change of applicant information